



**Validation**Institute

# 2021 Validation Report

**Review for: AllergyChoices**

**Validation Achieved: Level 2 - Outcomes**

**Valid through July 2022**



# Company Profile



---

<b>Category:</b>	Disease Management
<b>Website:</b>	<a href="http://www.allergychoices.com">www.allergychoices.com</a>
<b>Public or Private:</b>	Private
<b>Year Established:</b>	2000
<b>CEO:</b>	Jeff Kessler, MBA, FACHE
<b>Company contact:</b>	Abby Stensrud astensrud@allergychoices.com

## Description:

**Allergychoices** Allergy Control Program helps employers, benefits consultants and providers identify costs of allergic diseases (asthma, sinusitis, eczema, etc.) and implement streamlined diagnostics and disease-modifying sublingual immunotherapy that significantly reduces long and short-term costs, improves productivity, outcomes and quality of life. Works seamlessly through onsite, nearsite and primary care providers.





# Claim Assertion for Validation

---

**AllergyChoices** offers disease-modifying treatment of allergies. The course of sublingual immunotherapy (SLIT) can eliminate the need for future allergy treatment. Patients who complete the treatment have improved quality of life.





# Method / Calculation / Examples

---

This study was a prospective analysis that compiled and compared collected Juniper Rhino-conjunctivitis Quality of Life survey data from patients undergoing sublingual immunotherapy. Collected data for each patient were compared to that particular patient's baseline data and the same data from two subsequent patient visits.





## Findings & Validation

---

Two hundred and ninety-nine patients who had an average of 11 months of treatment completed the Juniper questionnaire at baseline, and at two follow-up visits. They showed statistically significant improvement in the six of the seven domains of quality of life scores from baseline to the end of treatment. Improvements were seen in the activities, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional categories; improvement was not statistically significant for sleep problems.



# Limitations

---

Adjustments were not made to weigh the self-selection bias among respondents.



# Validation and Credibility Guarantee

---

**AllergyChoices' Allergy Control Program** achieved level 2 validation for Outcomes. Validation Institute is willing to provide up to a \$25,000 guarantee as part of their Credibility Guarantee Program. To learn more, visit <https://validationinstitute.com/credibility-guarantee/>

## Level 1 – Savings

Can reduce health care spending per patient/participant or for the plan/purchaser overall.

## Level 2 – Outcomes

Product/solution has measurable moved the needle on an outcome (risk, hba1c, events, employee retention, etc.) of importance.

## Level 3 – Metrics

Credible sources and valid assumptions create a reasonable estimate of a program's impact.

## Level 4 - Contractual Integrity

No outcomes or savings has been shown, but vendor is willing to put a part of their fees "at risk" as a guarantee.





**Validation Expiration: July 2022**

# CERTIFICATE OF VALIDATION

---

**Applicant:**

**AllergyChoices**

2731 National Dr

Onalaska, Wisconsin, 54650

**Product:**

Allergy Control Program

**Claim:**

The course of sublingual immunotherapy (SLIT) can eliminate the need for future allergy treatment, which provides an improved quality of life.

**Validation Achieved:**

**Level 2 - Validated for Outcomes**

---

**Linda Riddell**

**VP, Population Health Scientist**

**Validation Institute**

---

**Benny DiCecca**

**Chief Executive Officer**

**Validation Institute**



# About Validation Institute

---

**Validation Institute** is a professional community that advocates for organizations and approaches that deliver better health value - stronger health outcomes at lower cost. We connect, train, and certify health care purchasers, and we validate and connect providers delivering superior results. Founded in 2014, the mission of the organization has consistently been to help provide transparency to buyers of health care.